Recombined Formulation
Non-healing Skin Ulcers
Not SpecifiedActive
Key Facts
About Reponex
Founded in 2018, Reponex Pharmaceuticals is a clinical-stage biotech focused on transforming patient care in oncology and immunology through its innovative '3R' drug development platform. The company has built a pipeline targeting acute and chronic conditions like bacterial peritonitis, colorectal cancer, and IBD by creatively reformulating and recombining known compounds, thereby reducing development risk and time. As a publicly traded subsidiary of Pharma Equity Group (Nasdaq Copenhagen: PEG), Reponex employs a capital-efficient, outsourced model to advance programs to Phase II proof-of-concept, aiming to create significant value through validated clinical data.
View full company profile